National Cancer Institute (NCI)

328 Protocols (226 Active Accrual of new subjects, 102 Follow-up of previously enrolled subjects)

 08-C-0214:

A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases

 08-C-0208:

Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer

 08-C-0180:

Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

 08-C-0179:

A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children with Refractory Solid Tumors

 08-C-0168:

A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas

 08-C-0166:

An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults with Non-Small Cell Lung Cancer (NSCLC)

 08-C-0164:

A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-cell Lymphoma Following Prior Systemic Therapy

 08-C-0162:

Transfer of Autologous T Cells Transduced with the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma

 08-C-0155:

Phase II Study of Metastatic Cancer that Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination

 08-C-0151:

A Pilot Study of Sirolimus (Rapamycin, Rapammune[Registered Trademark]) in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

 08-C-0130:

A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas

 08-C-0128:

A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors

 08-C-0123:

A Phase 1, Single Center, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (pALL) or Non-Hodgkin's Lymphoma (NHL)

 08-C-0121:

Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes

 08-C-0105:

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

 08-C-0104:

Phase II Study in Patients with Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin

 08-C-0101:

A Phase 2 Trial of Tandutinib in Combination with Bevacizumab for Patients with Recurrent High-Grade Gliomas

 08-C-0097:

Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults

 08-C-0096:

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas

 08-C-0092:

A Phase I Study with an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined with Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers and Familial Breast and Ovarian Cancer

 08-C-0091:

Phase I Study of SNX-5422 Mesylate in Adults with Refractory Solid Tumor Malignancies and Lymphomas

 08-C-0088:

Low Intensity Allogeneic Hematopietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells

 08-C-0087:

Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults with Solid Tumors and Lymphomas

 08-C-0086:

A Phase 2, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regime and Failure of Prior Treatment with Erlotinib

 08-C-0083:

Registration Ph III Study of Lucanix ™ (Trademark) in Adv NSC Lung Cancer: An Intl Mltctr RDBPC Study of Lucanix™ (Trademark) Maint Ther for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Dx Following One Reg of Front-line, P

 08-C-0080:

SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the IGF-1 Receptor for the Treatment of Patients with Recurrent or Refractory Ewing's Sarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas

 08-C-0079:

Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1

 08-C-0078:

A Phase I/II trial of Pemetrexed (Alimta [Registered Trademark]) Combined with Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects with Relapsed or Refractory NSCLC Whose Tumors Bear Activation of mTOR

 08-C-0077:

A Phase I, Multi-Institutional, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects with Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates For Standard Tx

 08-C-0075:

Phase III Evaluation of Recombinant MAGE-A3 Vaccine as Adjuvant Therapy Following Resection of MAGE-A3-Positive Non-Small Cell Lung Cancer

 08-C-0074:

A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)

 08-C-0071:

Phase I Study of Bortezomib and Cetuximab without or with Cisplatin in Combination with Radiation Therapy for Advanced Head and Neck Cancer

 08-C-0051:

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies

 08-C-0039:

A Phase II Study of ZD6474 (Vandetanib) in Subjects with Advanced Clear Cell Renal Carcinoma

 08-C-0035:

A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1® (Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues

 08-C-0033:

Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma

 08-C-0030:

Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

 08-C-0026:

A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma

 08-C-0020:

A Phase 2 Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors

 08-C-0015:

A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas

 08-C-0010:

Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors

 08-C-0007:

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer

 07-C-0230:

A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases

 07-C-0228:

Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

 07-C-0222:

Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma

 07-C-0220:

A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors

 07-C-0210:

Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma

 07-C-0206:

A Pilot Study of Tumor Vaccination in Patients with High Risk Pediatric Solid Tumors and Altered T Cell Homeostasis

 07-C-0203:

A Phase I Study of ABT-888 in Combination with Topotecan Hydrochloride in Adults with Refractory Solid Tumors and Lymphomas

 07-C-0200:

A Phase 1, Multicenter, Dose-Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

 07-C-0195:

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-Versus-Host Disease Prophylaxis Regimens

 07-C-0189:

Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma

 07-C-0188:

A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men with D0 Prostate Cancer Following Limited Androgen Ablation

 07-C-0176:

A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma

 07-C-0175:

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes

 07-C-0174:

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes

 07-C-0166:

A Phase I Study of BMS-354825 (DASATINIB) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistent PH Plus Leukemia

 07-C-0134:

A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid ® (Registered Trademark)), Oral Sunitinib (Sutent) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma

 07-C-0133:

Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma

 07-C-0130:

A Phase 1, Multicenter, Dose-Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)

 07-C-0123:

Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer

 07-C-0121:

A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma (PRC)

 07-C-0114:

A Phase I Study of Subcutaneous CYT 107 (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma

 07-C-0111:

A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies

 07-C-0110:

Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols

 07-C-0108:

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)

 07-C-0107:

A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer

 07-C-0106:

A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer

 07-C-0101:

A Phase 0 Trial of (111)Indium CHX-A" DTPA trastuzumab Imaging in Cancer

 07-C-0100:

Collection of Blood from Patients with Prostate Cancer

 07-C-0097:

A Phase I Study of Batracylin (NSC320846) in Subjects with Solid Tumors and Lymphomas

 07-C-0087:

A Natural History Study of HIV Acquired in Infancy or Childhood

 07-C-0086:

Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures

 07-C-0085:

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults with Metastatic, Recurrent, or Progressive Cancer or HIV Disease

 07-C-0081:

A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

 07-C-0074:

A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children with Relapsed or Refractory Neuroblastoma

 07-C-0064:

Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation with Costimulated, Tumor-Derived Lymphocytes

 07-C-0061:

Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the VEGFR2 Inhibitor, Vandetanib in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 07-C-0060:

Prospective Evaluation of Tumor Angiogenesis in Endocrine Neoplasms

 07-C-0059:

A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer

 07-C-0058:

A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer

 07-C-0054:

A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents with Relapsed or Refractory Solid Tumors

 07-C-0053:

A Phase I Trial of Enzastaurin (LY317615) in Combination with Carboplatin in Adults with Recurrent Gliomas

 07-C-0052:

A Phase 2 Study of O6-Benzylguanine (O(6)-BG) and Temozolomide in Patients with Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment with Radiation Therapy and Temozolomide

 07-C-0047:

A Phase I Trial of Nelfinavir (Viracept) in Adults with Solid Tumors

 07-C-0043:

An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects with Primary and Metastatic Cancer Undergoing Surgical Resection

 07-C-0040:

A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors

 07-C-0006:

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies

 07-C-0003:

Phase II Study of Metastatic Cancer that Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes

 06-C-0250:

A Phase II Trial of Bevacizumab and Irinotecan for Patients with Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)

 06-C-0233:

A Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias

 06-C-0221:

A Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Advanced Malignancies

 06-C-0219:

An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors

 06-C-0211:

A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance

 06-C-0204:

A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery that Results in the Removal of Both Ovaries

 06-C-0198:

A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

 06-C-0177:

Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia

 06-C-0169:

Phase II Study in Metastatic Melanoma or Kidney Cancer using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy

 06-C-0167:

A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects with Advance Solid Organ Malignancies

 06-C-0164:

A Phase II Study of BAY 43-9006 (Sorafenib) in Combination with Cetuximab (Erbitux) in EGFR Expressing Metastatic Colorectal Cancer (CRC)

Next 100 Protocols

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/17/2008